期刊
SEMINARS IN THROMBOSIS AND HEMOSTASIS
卷 34, 期 3, 页码 251-255出版社
THIEME MEDICAL PUBL INC
DOI: 10.1055/s-0028-1082268
关键词
tissue factor; antiphospholipid syndrome; antiphospholipid antibodies; tissue factor pathway inhibitor; thrombosis
The antiphospholipid syndrome (APS) is characterized by clinical manifestations such as venous and arterial thrombosis, thrombocytopenia and/or recurrent pregnancy loss, as well as the persistent presence of laboratory markers of antiphospholipid (aPL) antibodies detected in laboratory assays. Though it is generally accepted that aPL antibodies, such as anticardiolipin (aCL), anti-beta 2 glycoprotein I (anti-beta 2GPI), and lupus anticoagulants (LA) contribute to the pathogenesis of APS, precise mechanism(s) are vet to be fully described. It is probable that aPL antibodies bind to a range of cellular targets (e.g., platelets, endothelial cells, and monocytes), leading to thrombosis and obstetric complications. There is now increasing evidence that alterations to the tissue factor (TF) pathway of blood coagulation contribute toward hypercoagulability in patients with aPL antibodies. This article reviews current evidence that suggests changes and/or interference to the major pathway of blood coagulation may represent a novel mechanism that contributes to the development of APS.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据